DOP2002000337A - Inhibidores de metaloproteinasas de matriz basados en pirimidinas fusionadas - Google Patents
Inhibidores de metaloproteinasas de matriz basados en pirimidinas fusionadasInfo
- Publication number
- DOP2002000337A DOP2002000337A DO2002000337A DO2002000337A DOP2002000337A DO P2002000337 A DOP2002000337 A DO P2002000337A DO 2002000337 A DO2002000337 A DO 2002000337A DO 2002000337 A DO2002000337 A DO 2002000337A DO P2002000337 A DOP2002000337 A DO P2002000337A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- alkyl
- hydrogen
- fusioned
- pyrimidins
- inhibitors based
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Son inhibidores selectivos de MMP-13 las pirimidinonas fusionadas de formula. o una sal farmacéuticamente aceptable de las mismas; en donde: W, junto con los átomos de carbono a los cuales está unido, forma un dirradical anular de 5 miembros X es o, s, So, so2, NR5, ó CH2 A es -C- ó -S-; B es O o bien NR5 o bien A y B son tomados juntos para formar -CC-; R, R4, y R5 son hidrógeno, alquilo, alquenilo, alquinilo, CH2-ari1o, CH2-cic1oa1qui1o, alcanoílo C1-C6, ó CH2 -heteroari1o; R2 y R3 son hidrógeno, alquilo, alquenilo, alquinilo, CN, N02, NR4R5, CH2-cic1oa1qui1o, CH2-ari1o, ó CH2 -heteroari1o; R2 puede ser, además, halo; n es un número entero de O a 5; y R4 y R5, cuando son tomados junto con el nitrógeno al cual están unidos, completan un anillo de 3 a 8 miembros que contiene átomos de carbono y contiene opciona1meite o, S, o bien N, y está sustituido o sin sustituir; con la salvedad de que R y R3 no estén ambos seleccionados de hidrógeno y alquilo C1-C6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26875601P | 2001-02-14 | 2001-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2002000337A true DOP2002000337A (es) | 2002-08-15 |
Family
ID=23024328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2002000337A DOP2002000337A (es) | 2001-02-14 | 2002-02-01 | Inhibidores de metaloproteinasas de matriz basados en pirimidinas fusionadas |
Country Status (15)
Country | Link |
---|---|
US (1) | US20030004172A1 (es) |
EP (1) | EP1370562A1 (es) |
JP (1) | JP2004518732A (es) |
BR (1) | BR0207216A (es) |
CA (1) | CA2433778A1 (es) |
DO (1) | DOP2002000337A (es) |
GT (1) | GT200200017A (es) |
HN (1) | HN2002000029A (es) |
MX (1) | MXPA03004926A (es) |
PA (1) | PA8538301A1 (es) |
PE (1) | PE20020957A1 (es) |
SV (1) | SV2003000882A (es) |
TN (1) | TNSN02009A1 (es) |
UY (1) | UY27159A1 (es) |
WO (1) | WO2002064598A1 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2002000334A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
US8329924B2 (en) * | 2001-06-11 | 2012-12-11 | Vertex Pharmaceuticals (Canada) Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
KR100900304B1 (ko) * | 2001-06-11 | 2009-06-02 | 바이로켐 파마 인코포레이티드 | 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체 |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
JP4164028B2 (ja) | 2001-10-12 | 2008-10-08 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アルキンマトリックスメタロプロテイナーゼ阻害剤 |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
BR0312943A (pt) * | 2002-07-17 | 2005-07-12 | Warner Lambert Co | Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib |
CA2495432A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
CA2492379A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
EP1530472A1 (en) * | 2002-08-13 | 2005-05-18 | Warner-Lambert Company LLC | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
AU2003249531A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
WO2004014365A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
EP1394159A1 (fr) * | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
JP2006501215A (ja) | 2002-08-13 | 2006-01-12 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体 |
PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
AU2003250465A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
EP1537090A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
ES2283851T3 (es) | 2002-08-13 | 2007-11-01 | Warner-Lambert Company Llc | Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz. |
AU2003249477A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
WO2004014916A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
CN100360538C (zh) | 2003-01-29 | 2008-01-09 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
JP2008094846A (ja) * | 2003-01-29 | 2008-04-24 | Takeda Chem Ind Ltd | チエノピリミジン化合物およびその用途 |
US7247654B2 (en) | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
US7570259B2 (en) | 2004-06-01 | 2009-08-04 | Intel Corporation | System to manage display power consumption |
ES2310861T3 (es) | 2004-12-08 | 2009-01-16 | Bristol-Myers Squibb Company | Compuestos heterociclicos como inhibidores del factor viia. |
WO2007103776A2 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
KR20090043583A (ko) * | 2006-08-23 | 2009-05-06 | 뉴로젠 코포레이션 | 2-펜옥시 피리미디논 유사체 |
WO2008070529A2 (en) * | 2006-12-01 | 2008-06-12 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
EP1939197A1 (en) | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
WO2008138126A1 (en) * | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
AR077898A1 (es) | 2009-08-26 | 2011-09-28 | Nycomed Gmbh | Metilpirrolopirimidincarboxamidas |
CA2855372C (en) * | 2011-11-11 | 2022-03-22 | Nimbus Apollo, Inc. | 2,4-dioxo-thieno[2,3-d]pyrimidinyl derivatives and pharmaceutical compositions thereof used as acc inhibitors |
KR20160065957A (ko) * | 2013-10-07 | 2016-06-09 | 바이엘 파마 악티엔게젤샤프트 | 시클릭 티에노우라실-카르복스아미드 및 그의 용도 |
UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
AR106472A1 (es) * | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
WO2017091602A1 (en) | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Ester acc inhibitors and uses thereof |
EA201890910A1 (ru) | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА |
CN108349995B (zh) | 2015-11-25 | 2021-08-03 | 吉利德阿波罗公司 | 吡唑acc抑制剂及其用途 |
PL3380479T3 (pl) | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Triazolowe inhibitory acc i ich zastosowania |
TWI818828B (zh) | 2016-03-02 | 2023-10-11 | 美商基利阿波羅有限責任公司 | 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法 |
WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
KR20190053242A (ko) | 2016-09-23 | 2019-05-17 | 바이엘 악티엔게젤샤프트 | N3-시클릭 치환된 티에노우라실 및 그의 용도 |
EP4122464B1 (en) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
CN110183464B (zh) * | 2019-05-31 | 2021-08-31 | 淮阴工学院 | 一种抗癌化合物艾斯替尼及其合成方法和应用 |
KR102649886B1 (ko) * | 2021-07-21 | 2024-03-22 | 충남대학교산학협력단 | 신규한 피리미딘-4-온 화합물 및 이를 포함하는 항암제 조성물 |
WO2024036183A1 (en) * | 2022-08-09 | 2024-02-15 | Vanderbilt University | Antagonists of 5-hydroxytryptamine receptor subtype 2b |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155665A (en) | 1961-04-26 | 1964-11-03 | Searle & Co | 4, 6-dialkyl-5, 7-diketothiazolo [4, 5-d] pyrimidine-2-carboxylic acid and derivatives thereof |
US3277093A (en) | 1965-08-02 | 1966-10-04 | Searle & Co | (optionally-2-substituted) 4-halophenyl-5, 7-diketo-6-alkylthiazolo[4, 5-d]pyrimidines |
GB8601371D0 (en) | 1986-01-21 | 1986-02-26 | Beecham Group Plc | Compounds |
US6140325A (en) * | 1993-08-19 | 2000-10-31 | Takeda Chemical Industries, Ltd. | Thienopyrimidine derivatives, their production and use |
US6048863A (en) * | 1994-04-19 | 2000-04-11 | Takeda Chemical Industries, Ltd. | Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use |
ATE225351T1 (de) * | 1994-11-08 | 2002-10-15 | Takeda Chemical Industries Ltd | Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel |
US5792767A (en) * | 1995-01-27 | 1998-08-11 | Abbott Laboratories | Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists |
EP0915093B1 (en) * | 1996-06-06 | 2002-11-27 | Otsuka Pharmaceutical Factory, Inc. | Amide derivatives |
SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
US6469014B1 (en) * | 1997-05-28 | 2002-10-22 | Astrazeneca Ab | Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy |
US6166019A (en) * | 1998-07-16 | 2000-12-26 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
JP2002523511A (ja) * | 1998-08-28 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
DE19940494C1 (de) * | 1999-08-26 | 2001-02-15 | Ibfb Gmbh Privates Inst Fuer B | Mehrcyclische Pyrimidin-2,4(1H,3H)-dione mit funktionalisierten Alkylresten in 1- und/oder 3-Position, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen |
PA8539501A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
US6924276B2 (en) * | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
WO2004014916A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
US20050004111A1 (en) * | 2003-01-03 | 2005-01-06 | Aventis Pharma Deutschland Gmbh | Selective MMP-13 inhibitors |
-
2002
- 2002-01-18 WO PCT/IB2002/000204 patent/WO2002064598A1/en not_active Application Discontinuation
- 2002-01-18 EP EP02711123A patent/EP1370562A1/en not_active Withdrawn
- 2002-01-18 BR BR0207216-5A patent/BR0207216A/pt not_active IP Right Cessation
- 2002-01-18 CA CA002433778A patent/CA2433778A1/en not_active Abandoned
- 2002-01-18 JP JP2002564529A patent/JP2004518732A/ja not_active Abandoned
- 2002-01-18 MX MXPA03004926A patent/MXPA03004926A/es unknown
- 2002-02-01 DO DO2002000337A patent/DOP2002000337A/es unknown
- 2002-02-05 PA PA20028538301A patent/PA8538301A1/es unknown
- 2002-02-07 GT GT200200017A patent/GT200200017A/es unknown
- 2002-02-08 UY UY27159A patent/UY27159A1/es not_active Application Discontinuation
- 2002-02-11 HN HN2002000029A patent/HN2002000029A/es unknown
- 2002-02-12 PE PE2002000110A patent/PE20020957A1/es not_active Application Discontinuation
- 2002-02-13 US US10/075,073 patent/US20030004172A1/en not_active Abandoned
- 2002-02-13 TN TNTNSN02009A patent/TNSN02009A1/fr unknown
- 2002-02-13 SV SV2002000882A patent/SV2003000882A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SV2003000882A (es) | 2003-01-13 |
PE20020957A1 (es) | 2002-11-08 |
EP1370562A1 (en) | 2003-12-17 |
BR0207216A (pt) | 2004-03-09 |
WO2002064598A1 (en) | 2002-08-22 |
CA2433778A1 (en) | 2002-08-22 |
TNSN02009A1 (fr) | 2005-12-23 |
HN2002000029A (es) | 2003-02-14 |
GT200200017A (es) | 2002-11-15 |
PA8538301A1 (es) | 2002-09-17 |
UY27159A1 (es) | 2002-09-30 |
US20030004172A1 (en) | 2003-01-02 |
JP2004518732A (ja) | 2004-06-24 |
MXPA03004926A (es) | 2005-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2002000337A (es) | Inhibidores de metaloproteinasas de matriz basados en pirimidinas fusionadas | |
ECSP034691A (es) | Inhibidores de piridina de metaloproteinasas de la matriz | |
PA8538401A1 (es) | Pirimidinas inhibidoras de metaloproteinasas de matriz | |
WO2003068750A1 (fr) | Inhibiteur de jnk | |
CY1112108T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
ES2186821T3 (es) | Derivados de 6- bencil- 2h-piridazin-3-ona, su preparacion y s u uso como inhibidores de la prostaglandin-g/h sintasa i y ii (cox i y cox ii). | |
TR200100432T2 (tr) | Hepatit C inhibitörü tri-peptidler | |
EP1295867A4 (en) | biphenyl | |
ES2191985T3 (es) | S-oxido de tetrahidrotiopirano feniloxazolidinonas. | |
AR027218A1 (es) | Inhibicion de polimerizacion de monomeros insaturados | |
BG102647A (en) | Acyclic nucleoside derivatives | |
DE69841374D1 (de) | 3-o-sulfamatsteroidderivate als hemmer von estronsulfatase | |
DE69834271D1 (de) | Steroid-3-o-sulfamat-derivate als estronsulfatase-hemmer | |
CY1117806T1 (el) | Διαταξη ελατηριου αεριου με προστατευτικο χιτωνιο που τοποθετειται πριν το βαψιμο | |
ES2194102T3 (es) | Nuevas n-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas. | |
CO5080758A1 (es) | DERIVADOS DE 3-(2-oxo-[1,3´]BIPIRROLODINIL-3-ILIDENMETIL | |
TR199701298T1 (xx) | Tetralinler. | |
CO5011097A1 (es) | Derivados de 8-azabiciclo [3.2.1]octan-3-metanamina . | |
UA26459C2 (uk) | Іhгібітор впливу амілоїдhих білків | |
EA199700395A1 (ru) | Способ получения ингибиторов протеазы вируса иммунодефицита человека | |
EA199900684A1 (ru) | Производные иминоазаантрациклинона для лечения амилоидоза | |
ES2098846T3 (es) | Eteres de oxima y copolimeros que contienen estos. | |
KR960703595A (ko) | 항우울제(antidepressant) | |
DK0725776T3 (da) | 3-Aryl-4-alkyl- og 4,5-dialkyl-4H-1,2,4-triazoler anvendelige som hukommelsesforbedrende midler | |
CO5040081A1 (es) | Nuevos compuestos vidad farmaaceutica |